Johnson & Johnson Reports Promising Phase 3 Data for Icotrokinra in Plaque Psoriasis, Launches Head-to-Head Study

Johnson & Johnson announced new icotrokinra (JNJ-2113) data from its comprehensive Phase 3 clinical program and the start of the first-ever head-t...

March 10, 2025 | Monday | News
Lindus Health and Tiefenbacher Group Partner on Virtual Phase 2 Trial for ME/CFS Treatment

 Lindus Health, the "anti-CRO" running radically faster, more reliable clinical trials, and Tiefenbacher Group, a leading healthcare company...

March 07, 2025 | Friday | News
ImmunoGenesis Doses First Patient in Phase 1/2 Trial of IMGS-101 Combination Therapy for Advanced Cancers

ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, announced the first patient has been dosed in the co...

March 07, 2025 | Friday | News
Akeso’s Ivonescimab Phase III Study Results Published in The Lancet, Paving the Way for New NSCLC Treatment

Akeso, Inc. is excited to announce that the groundbreaking results of the Phase III clinical study (HARMONi-2/AK112-303) of its first-in-class PD-1/VE...

March 07, 2025 | Friday | News
iTeos Therapeutics Reports Strong 2024 Financial Results and Strategic Update for 2025

iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology treatm...

March 07, 2025 | Friday | News
Acadia Reports Positive DAFFODIL™ Study Results for DAYBUE® in Rett Syndrome

Acadia Pharmaceuticals Inc.  announced that the journal Med published results from the open-label study, DAFFODIL™, evaluating the saf...

March 06, 2025 | Thursday | News
BeiGene Wins FDA Approval for TEVIMBRA® in First-Line Esophageal Cancer Treatment

BeiGene, Ltd.  a global oncology company that intends to change its name to BeOne Medicines Ltd., announced the U.S. Food and Drug Administr...

March 06, 2025 | Thursday | News
Neurocrine Biosciences Begins Phase 1 Trial for NBI-1140675 in Neurological Disorders

Neurocrine Biosciences, Inc. announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynami...

March 06, 2025 | Thursday | News
FDA Accepts Roche’s sBLA for Gazyva®/Gazyvaro® (Obinutuzumab) as a Treatment for Lupus Nephritis

Roche announced  that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for...

March 06, 2025 | Thursday | News
Roche Reports Positive Phase III OUtMATCH Data, Strengthening Xolair® for Food Allergies

Roche announced new positive data from Stage 2 and Stage 3 of the National Institutes of Health (NIH)-sponsored phase III OUtMATCH study, which provide fur...

March 06, 2025 | Thursday | News
Celon Pharma Announces Positive Phase 2 Results for CPL’36 in Treating Levodopa-Induced Dyskinesia in Parkinson's Disease

Celon Pharma S.A.  announces robust and positive Phase 2 clinical trial results for its PDE10A inhibitor (CPL’36), a novel, oral, once-daily med...

March 05, 2025 | Wednesday | News
GHIT Fund Marks Milestone with First Administration of Arpraziquantel to Preschool Children in Uganda

The Global Health Innovative Technology (GHIT) Fund is announcing a significant milestone: the first administration of arpraziquantel to preschool-aged chi...

March 05, 2025 | Wednesday | News
Advancements in Tenosynovial Giant Cell Tumor Treatment with Surgery and Targeted Therapies

Tenosynovial giant cell tumor, also known as pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath (GCT-TS), is primarily treate...

March 05, 2025 | Wednesday | News
CStone Begins Phase I Trial of CS2009 Trispecific Antibody for Solid Tumors

CStone Pharmaceuticals, an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, announced that&nbs...

March 04, 2025 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close